

Jikkyleaks (Fan Account)

Imagine that a new adenovirus emerges that we have never seen before, and it starts in the UK... And induces liver failure in children. Did it come from the same mechanism that #SARSCOV2 variant N501Y (the UK mouse strain) did?

Anastasis @OrdersofM

Tangential side note.. how come nobody is talking about how the entire building that was making JNJ and AZ is being abandoned after a contamination with adenovirus according to news sources

[https://www.nytimes.com/2021/04/21/us/politics/emergent-johnson-johnson-covid-vaccine.html?smid=tw-share&fbclid=IwAR3zHABj3rB4NbQecbaJey1u\\_pKXPTkB1Xl-11qJrMzo-6SVPZTVy0N---M](https://www.nytimes.com/2021/04/21/us/politics/emergent-johnson-johnson-covid-vaccine.html?smid=tw-share&fbclid=IwAR3zHABj3rB4NbQecbaJey1u_pKXPTkB1Xl-11qJrMzo-6SVPZTVy0N---M)

The screenshot shows a mobile browser interface. At the top, the status bar displays 'AT&T', signal strength, Wi-Fi, and battery icons, along with the time '12:23 PM' and the URL 'nytimes.com'. Below the status bar, the article title 'Emergent BioSolutions Investigation' is partially visible, followed by a sub-header 'The Troubled U.S. Stockpile' and 'Million o'. The main text of the article is highlighted in yellow and reads: 'The F.D.A. inspection began after routine checks showed that Emergent workers had contaminated at least part of a batch of 13 million to 15 million doses of the Johnson & Johnson vaccine with the harmless virus that is used to make the AstraZeneca shot. The regulators found that Emergent failed to thoroughly investigate that incident and performed only routine cleaning afterward. One previous audit of Bayview for a pharmaceutical customer found that Emergent glossed over deviations from manufacturing standards without conducting thorough reviews.' Below this, another paragraph begins: 'The inspectors, who examined security footage as part of their review, found that Emergent failed to consider whether one or more workers might have been the source of the contamination. Workers are supposed to change gowns and booties and shower before crossing between the different manufacturing zones for Johnson & Johnson and AstraZeneca'. At the bottom of the screenshot, there is a subscription offer: 'Subscribe for \$1 a week. Limited time offer.' and a small upward-pointing arrow icon.

Jikkyleaks (Fan Account)

From yesterday. Earlier cases all had adenovirus. UK cases mostly had adenovirus.

Current UKHSA report.

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1071198/acute-hepatitis-technical-briefing-1\\_4\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1071198/acute-hepatitis-technical-briefing-1_4_.pdf)

This is my current guess (highlighted)

The rollout of a never-before-tested DNA/RNA therapy across the world in record time not only resulted in new coronavirus variants but also a deattenuated (or new) adenovirus variant.

## 6.1 Working hypotheses (in order of best to worst fit to data)

1. A cofactor affecting young children which is rendering normal adenovirus infections more severe or causing them to trigger immunopathology. The cofactor may be:
  - a. susceptibility, for example due to lack of prior exposure during the pandemic
  - b. a prior infection with SARS-CoV-2 or another infection, including an Omicron restricted effect
  - c. a coinfection with SARS-CoV-2 or another infection
  - d. a toxin, drug or environmental exposure
2. A novel variant adenovirus, with or without a contribution from a cofactor as listed above.
3. A drug, toxin or environmental exposure.
4. A novel pathogen either acting alone or as a coinfection.
5. A new variant of SARS-CoV-2.









Figure 5. Adenovirus episodes from Faecal/GI samples by age and week of specimen, England 1 January 2017 to 17 April 2022: Supplementary data is not available for this figure.



Just a note to debunk the unverified "breast feeding" story which is likely disinformation.. The adenovirus rise is most prominent in 2-5 year olds in the UK. Breastfeeding rates are shockingly low in the UK (esp >6 months) so this pattern would discount this as a cause.



I'm sure it's nothing...

<b>Job Title</b>	<b>gb ADN06445.1 </b>		
<b>RID</b>	<a href="#">723BVA4X01N</a>	Search expires on 05-04 19:09 pm	
	<a href="#">Download All</a>	▼	
<b>Program</b>	BLASTP	<a href="#">?</a>	<a href="#">Citation</a> ▼
<b>Database</b>	nr	<a href="#">See details</a> ▼	
<b>Query ID</b>	<a href="#">ADN06445.1</a>		
<b>Description</b>	E2B DNA pol [Human adenovirus 41]		
<b>Molecule type</b>	amino acid		
<b>Query Length</b>	1187		
<b>Other reports</b>	<a href="#">Distance tree of results</a> <a href="#">Multiple alignment</a> <a href="#">MSA viewer</a> <a href="#">?</a>		
Query	326	FYVVTPEKMAVGKKFRNYRDRLLQTHFATQLWQAFLAANPQVAEWARLEM-GLFSPDNLTY FY VTPEKMAVG FR YRDRLLQ T A LW FL ANP+ A+WA LE GL PD LTY	384
Sbjct	333	FYCVTPEKMAVGQQFRQYRDRLLQ TALAVDLWTSFLRANPHLADWA-LEQHGLSDPDELTY	391
Query	385	EELKKAPKLQGTPRFVELYIVGHNINGFDEIVLAAQVINNRSDVPGPFKITRNFMPRAGK EELKK P G PRFVELYIVGHNINGFDEIVLAAQVINNR +VP PF ITRNFMPRAGK	444
Sbjct	392	EELKKLPHVKGRPRFVELYIVGHNINGFDEIVLAAQVINNRAEVPQPFTRITRNFMPRAGK	451
Query	445	ILFNDITFALPNPLSKKRTDYHLWEQGCDDTDFKHQFLKVMVRDTFALHTSLRKAQA ILFND+TFALPNP KKRTD++LWEQG CDD DFKHQFLKVMVRDTFALHTSLRKAQA	504
Sbjct	452	ILFNDVTFALPNPAYKKRTDFQLWEQGGCDDIDFKHQFLKVMVRDTFALHTSLRKAQA	511
Query	505	YALPVEKGCCPYKAVNQFYMLGSYRADERGFPAEDYWKDREEYLLNRELWEKKQOSRYDL YALPVEKGCC YKAVNQFYMLGSYRAD+ GFP E+YWKDREE+LLNRELW K Q YD	564
Sbjct	512	YALPVEKGCCAYKAVNQFYMLGSYRADQDGFPLEEYWKDREEFLLNRELWKQKGLKYDI	571
Query	565	IRETLDYCALDVLVTAALVQKLRESYAQFICDAVGLPEAKFNVFQRPTISSNSHAIFRQI I ETLDYCALDVLVTA LV KL +SYA+FI D VGLP A FN+FORPTISSNSHAIFRQI	624
Sbjct	572	IQETLDYCALDVLVTAELVAKLQDSYAHFIRDSVGLPHAHFIFQRPTISSNSHAIFRQI	631
Query	625	LYQSVKPKRSDLGNLLAPSHEMYDYVVRASIRGGRCYPTYIGVLRPLYVYDICGMYASA Y KP R +LG GLLAPSHYDYVVRASIRGGRCYPTYIG+L EPLYVYDICGMYASA	684
Sbjct	632	VYRAEKPSRTNLGPGLLAPSHELYDYVVRASIRGGRCYPTYIGILEEPLYVYDICGMYASA	691
Query	685	LTHPMPWGSPLNYPYERALAVRDWERALLQVD---TPIDYFNHVLLPGIFTIDADPPSEN LTHPMPWG PL PYERALAVR+W+ L D T I YF+ LLPGIFTIDADPP E +	741
Sbjct	692	LTHPMPWGTPLSPYERALAVREWQASL---DDLATSISYFDPDLLPGIFTIDADPPDEV M	748
Query	742	LDVLPYPYCSRKGGRLCWTNEPLRGEVATSIDLITLHNRGWQVRLLPDERTTVFPEWRCVA LD LPP+CSRKGGRLCWTNEPLRGEVATS+DLITLHNRGWQVR PDE TTVFPEW CVA	801
Sbjct	749	LDPLPPFCSRKGGRLCWTNEPLRGEVATSVDLITLHNRGWQVRIVPDEMTTVFPEWRCVA	808
Query	802	RKYVQLNIAAKERADREKNQTLRSIAKLLSNALYGSFATKLDNKKIVFSDQMDPATIKSI R YVQLNIAAKERAD EKNQT+RSIAKLLSNALYGSFATKLDNKKIVFSDQMD K I	861
Sbjct	809	REYVQLNIAAKERADKEKNQTMRSIAKLLSNALYGSFATKLDNKKIVFSDQMDDEGLLKI	868
Query	862	AAGQIKIKSTSFVETDLSAEVMPAFQRAYSPQLALAHSDAEESDEERGA-LYTP--- AG + IKS SF ETD LSAEVMFAF+R Y P+QLAL SD E+S++E G A YTP	917
Sbjct	869	SAGTVNIKSSSFLETDNLAEVMPAFEREYLPQQLALDSDPEDESEDEQGPAPFYTPAG	928
Query	918	TQDPKGHVITYTYKPITFMDAEEDDLCLHTLEKVDPLVENDRYPSQIASFVLAWTRAFVSE T P GHV YTYKPITF+D +E D+CLHTLEKVDPLV+NDRYPS++ASFVLAWTRAFVSE	977
Sbjct	929	T--P-GHVAYTYKPITFLDVEGDMCLHTLEKVDPLVDNDRYPSHVASFVLAWTRAFVSE	985
Query	978	WSEFLYAEDRGTPLERQTLKSVYGDTSFLVTEAGHRLMETRGKKRIKKGGSVLFDPKN W FLY EDRGTPLER R KSVYGDTSFLVFT+ GH LMET GKKRIKKG G LVFDP	1037
Sbjct	986	WAGFLYEEDRGTPLERPIKSVYGDTSFLVFTQRGHELMETGKKRIKKGGSVLFDPDQ	1045
Query	1038	PELTWLVECETCAQCGANAYSPEVFLAPKLYALKCLYCPSCQHISKGLRAKGHAAEA P+LTWLVECET CA+CGA+AY P+SVFLAPKLYALK L CP C + SKGKLRAGHAAEA	1097
Sbjct	1046	PDLTWLVECETVCAHCGADAYAPDSVFLAPKLYALKSLLCPACGQTSKGKLRAGHAAEA	1105
Query	1098	LSYELMLKCYLADSQGED-ARFHTSRMSLKRTLASAQPGAHPFTVTETTLTRTLRPWKDI L YELM CYLAD QG D RF TSRMSLKRTLASAQPGAHPFTVTETTLTRTLRPWKD	1156
Sbjct	1106	LNYELMVCYLADAQGADRERF+TSRMSLKRTLASAQPGAHPFTVTETTLTRTLRPWKDR	1165

## Virology [\[ edit \]](#)

ChAdOx1 has been derived from a chimpanzee adenovirus (ChAd) serotype Y25 engineered by  $\lambda$  red recombination to exchange the native E4 orf4, orf6 and orf6/7 genes for those from human adenovirus HAdV-C5.<sup>[2][3]</sup> Serotype Y25 belongs to the species *Human mastadenovirus E* of genus *Mastadenovirus*.  
*[citation needed]*

> Bing Du Xue Bao. 2007 Jul;23(4):258-64.

### [Improved replication of enteric adenovirus type 41 in Hep2 cell line expressing E1B55K]

[Article in Chinese]

Bing-juan Han <sup>1</sup>, Li Guo, Jian-guo Qu, Min Wang, Jian-Wei Wang, Zhuo-zhuang Lu, Tao Hong

Affiliations [+](#) expand


PMID: 17894226

#### Abstract

Adenovirus type 40 and 41 (Ad40, Ad41), which belong to human adenovirus subgroup F, are called fastidious adenoviruses due to their property of poor growth in cultured cell lines in vitro. The effect of expression of exogenous E1B55K in Hep2 on Ad41 replication in this cell line was investigated. E1B55K gene was amplified by PCR with DNA extracted from Ad41-positive feces supernatant as template. Eukaryotic expression plasmid (pcDNA3) carrying E1B55K was constructed, purified, and transferred into Hep2 cell. Expression of E1B55K in G418-resistant clones was assayed by RT-PCR, and one clone named as Hep2-E1B#4 could produce more Ad41 progenies when compared with other clones by the method of inducing complete cytopathic effect (CPE) in 293 cells. Infection of equivalent Ad41 caused more significant cytopathic effect (CPE) in Hep2-E1B#4 than that in the control cells of Hep2 or Hep2-DNA3, also suggesting enhanced viral replication in Hep2-E1B#4. The titer of Ad41 was further determined by method of immunocytochemical staining, and semi-quantity PCR was employed to compare the copy number of Ad41 genome DNA. The results showed that the yield of Ad41 in Hep2-E1B#4 was more than 9 times of that in control cells when equal amount of seed viruses were incubated, and the copy number of Ad41 genome increased 4 times in the raw extract from the infected Hep2-E1B#4 when compared with that from control cells. In conclusion, E1B55K gene transfer improved the ability of Hep2 in packaging Ad41, and the Hep2-E1B#4 cell line, which expressed E1B55K constitutively, would be helpful in isolation, cultivation and amplification of Ad41.

Also seems kind of important...


<https://gut.bmj.com/content/48/5/733>



And this.

If E1-deficient adenovirus vectors were to pick up the E1 gene components necessary for replication, they could deattenuate. It was a dangerous experiment performed by people who had no idea what they were doing on a global scale

[https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016\(02\)90589-7](https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(02)90589-7)



Er...

@SabinehazanMD

you might be interested in this...

Are attenuated adenoviruses picking up EB155K?

<https://www.ncbi.nlm.nih.gov/protein/UAW96097.1>

## EB1 55K protein large t antigen [Human mastadenovirus F]

GenBank: UAW96097.1

[Identical Proteins](#) [FASTA](#) [Graphics](#)

[Go to:](#)

```
LOCUS           UAW96097               472 aa               linear   ENV 22-SEP-2021
DEFINITION     MAG: EB1 55K protein large t antigen [Human mastadenovirus F].
ACCESSION     UAW96097
VERSION       UAW96097.1
DBLINK        BioProject: PRJNA729919
               BioSample: SAMN19188303
               Sequence Read Archive: SRR15186924, SRR15186925, SRR15186926,
               SRR15186927, SRR15186928, SRR15186929, SRR15186930, SRR15186931,
               SRR15186932, SRR15186933, SRR15186934, SRR15186935, SRR15186936,
               SRR15186937, SRR15186938, SRR15186939, SRR15186940, SRR15186941,
               SRR15186942, SRR15186943, SRR15186944, SRR15186945, SRR15186946,
               SRR15186947, SRR15186948, SRR15186950, SRR15186952, SRR15186953,
               SRR15186954, SRR15186955, SRR15186956, SRR15186957, SRR15186958,
               SRR15186959, SRR15186960, SRR15186961, SRR15186962, SRR15186963,
               SRR15186964, SRR15186965, SRR15186966, SRR15186968, SRR15186969,
               SRR15186970, SRR15186971, SRR15186972, SRR15186973, SRR15186974,
               SRR15186975, SRR15186976, SRR15186977, SRR15186978, SRR15186979,
               SRR15186980, SRR15186981, SRR15186984, SRR15186985, SRR15186986,
               SRR15186987, SRR15186988, SRR15186989, SRR15186990, SRR15186991,
               SRR15186992, SRR15186993, SRR15186994, SRR15186995, SRR15186996,
               SRR15186997, SRR15186999, SRR15187001, SRR15187002, SRR15187003,
               SRR15187004, SRR15187005, SRR15187006, SRR15187007, SRR15187008,
               SRR15187009, SRR15187010, SRR15187011, SRR15187012, SRR15187014,
               SRR15187015, SRR15187016, SRR15187017, SRR15187018, SRR15187019,
               SRR15187020, SRR15187021, SRR15187022, SRR15187023, SRR15187024,
               SRR15187025, SRR15186949, SRR15186951, SRR15186967, SRR15186982,
               SRR15186983, SRR15186998, SRR15187000, SRR15187013
               accession MZ603083.1
DBSOURCE      ENV; Metagenome Assembled Genome; MAG.
KEYWORDS      Human mastadenovirus F (human gut metagenome)
SOURCE        Human mastadenovirus F
ORGANISM      Human mastadenovirus F
               Viruses; Varidnaviria; Bamfordvirae; Preplasmiviricota;
               Tectiliviricetes; Rowavirales; Adenoviridae; Mastadenovirus.
REFERENCE     1 (residues 1 to 472)
AUTHORS       Simsek,C., Bloemen,M., Jansen,D., Beller,L., Descheemaeker,P.,
               Reynders,M., Van Ranst,M. and Matthijnsens,J.
TITLE         High prevalence of co-infecting enteropathogens in suspected
               rotavirus vaccine breakthrough cases
JOURNAL       Unpublished
REFERENCE     2 (residues 1 to 472)
AUTHORS       Simsek,C. and Matthijnsens,J.
               Tectiliviricetes; Rowavirales; Adenoviridae; Mastadenovirus.
REFERENCE     1 (residues 1 to 472)
AUTHORS       Simsek,C., Bloemen,M., Jansen,D., Beller,L., Descheemaeker,P.,
               Reynders,M., Van Ranst,M. and Matthijnsens,J.
TITLE         High prevalence of co-infecting enteropathogens in suspected
               rotavirus vaccine breakthrough cases
JOURNAL       Unpublished
REFERENCE     2 (residues 1 to 472)
AUTHORS       Simsek,C. and Matthijnsens,J.
TITLE         Direct Submission
JOURNAL       Submitted (09-JUN-2021) Microbiology, Immunology and
               Transplantation, Rega Institute, KU Leuven, Herestraat 49, Leuven
               3000, Belgium
COMMENT       Method: conceptual translation.
FEATURES      Location/Qualifiers
               source                1..472
               /organism="Human mastadenovirus F"
               /isolate="HAdV-41_RVAB"
               /isolation_source="feces"
               /db_xref="taxon:130309"
               /environmental_sample
               /collection_date="2011"
               /metagenome_source="human gut metagenome"
               /note="metagenomic"
               Protein                1..472
               /product="EB1 55K protein large t antigen"
```

So the two possibilities are

- (1) Research using attenuated adenoviruses have leaked into the community or
- (2) The original #ChAdOx1 vaccine has deattenuated.

I now favour (2)...

What that means is that the vaccine virus picks up the E1 gene (in whole or part) from another circulating adenovirus (there are many).

A replicative ChAdOx1 results.

Most people will be immune because they have been exposed to adenoviruses throughout their life...

But young children who haven't been exposed to intestinal adenoviruses are now hit with a supercharged (chimaeric) adenovirus as their first exposure.

It's supercharged because it is not only an adenovirus but now also expresses the toxic spike protein from #SARSCOV2

Potentially resulting in a devastating double whammy to young (adenovirus-naive) children.

This kind of GMO disaster scenario was absolutely why genome regulators were created. They completely failed.

<https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-180>

**Description:**

This licence allows AstraZeneca Pty Ltd to import and distribute their COVID-19 vaccine as part of its commercial supply as a vaccine in Australia. The [Therapeutic Goods Administration](#) (TGA) has responsibility for assessing the quality, safety and efficacy of any vaccine intended for use in people in Australia. . Once approved for use in Australia, products are registered by the TGA and can then be distributed. You can find out more about the TGA approval of the AstraZeneca vaccine on their website.

The Regulator has not imposed any specific measures to manage risk because there is negligible risk to the health and safety of people or the environment. Supply of the vaccine will follow the [Australian code of good wholesaling practice for medicines in schedules 2, 3, 4 & 8 \(2011\)](#), the [WHO's Good Distribution Practices for pharmaceutical products \(WHO 2010\)](#), the [National Vaccine Storage Guidelines: Strive for 5 \(2019\)](#) and the [Standard for the Uniform Scheduling of Medicines and Poisons \(as current\)](#) which all provide appropriate controls and informed the risk assessment. Any unused vaccine or waste material will be disposed of in accordance with local requirements for clinical waste.

The risk analysis for this application was carried out in accordance with the [Regulator's Risk Analysis Framework](#).

**Date application received:**

7 December 2020